Abacavir/Lamivudine

DRUG13 trials

Sponsors

ViiV Healthcare, GlaxoSmithKline, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Pfizer, Therapeutic Concepts

Conditions

Antiretroviral Therapy IntoleranceHIV InfectionHIV InfectionsHIV-1 InfectionHIV-1-infectionHealthy VolunteersHiV1- PositiveInfection, Human Immunodeficiency Virus

Phase 1

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects

CompletedNCT01220232

PfizerHealthy Volunteers

Start: 2010-11-30End: 2011-01-31Updated: 2011-02-04

Phase 3

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

CompletedNCT00044577

ViiV HealthcareHIV Infection, Infection, Human Immunodeficiency Virus I

Start: 2002-07-16End: 2004-05-25Target: 166Updated: 2020-03-24

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

CompletedNCT00046176

ViiV HealthcareHIV Infection, Infection, Human Immunodeficiency Virus I

Start: 2002-08-26End: 2004-05-17Target: 240Updated: 2020-03-24

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

CompletedNCT00053638

GlaxoSmithKlineHIV Infection

Start: 2003-02-28End: 2004-10-31Target: 345Updated: 2010-10-04

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

CompletedNCT00085943

GlaxoSmithKlineHIV Infection, Infection, Human Immunodeficiency Virus

Start: 2004-05-31Target: 866Updated: 2011-05-16

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

CompletedNCT00094367

GlaxoSmithKlineHIV Infection

Start: 2004-07-31End: 2005-10-31Target: 900Updated: 2010-09-30

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

CompletedNCT00118898

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsHIV Infections

Start: 2005-09-30End: 2009-11-30Updated: 2018-10-12

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

CompletedNCT01263015

ViiV HealthcareInfection, Human Immunodeficiency Virus I

Start: 2011-02-01End: 2015-12-03Updated: 2018-04-04

Study of Options for Second-Line Effective Combination Therapy (SELECT)

CompletedNCT01352715

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsHIV-1 Infection

Start: 2012-03-13End: 2014-10-29Updated: 2021-08-05

Phase 4

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

CompletedNCT00244712

GlaxoSmithKlineHIV Infection

Start: 2005-07-31End: 2008-04-30Updated: 2010-06-08

Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy

CompletedNCT01608269

Therapeutic ConceptsHiV1- Positive

Start: 2010-11-30End: 2012-10-31Target: 30Updated: 2017-04-28

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

WithdrawnNCT02470650

Juan A. ArnaizAntiretroviral Therapy Intolerance, Patient Compliance

Start: 2015-06-30End: 2017-10-31Updated: 2025-07-30

Unknown Phase

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

CompletedNCT04301661

University of Colorado, DenverHIV-1-infection

Start: 2020-03-06End: 2021-12-17Updated: 2023-01-09

Related Papers

Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings

AIDS Care2021-01-238 citations

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202

Antimicrobial Agents and Chemotherapy2019-01-1416 citations

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.

2016-04-1861 citations

Safety and Efficacy of DTG Plus ABC/3TC for Treatment-Naive Patients with HIV

MD Conference Express2014-11-01

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.

2014-07-01147 citations

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

2013-11-1825 citations

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

New England Journal of Medicine2013-11-06862 citations

Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

2012-11-2950 citations

HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.

2012-11-1218 citations

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

2011-07-0199 citations

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

2011-06-01367 citations

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

2011-02-14241 citations

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

2009-12-01224 citations